Otsuka Pharmaceutical Factory and ICU Medical establish IV solution joint venture

Otsuka Pharmaceutical Factory America (OPFA) will acquire a 60% stake in a new IV solution company formed with ICU Medical, which will transfer its IV solution business to the new entity. The agreement was signed on November 12, 2024, and operations are expected to begin in early Q2 2025.

“OPFA will obtain 60% shares of the new company, which will then become a subsidiary of OPFA, inaugurating OPFA's foray into the North American IV solution business.”otsukakj.jp

• 1 source
• otsukakj.jpOtsuka Pharmaceutical Factory and ICU Medical Announce the Establishment of Joint Venture | NEWS | Otsuka Pharmaceutical FactoryNov 13, 2024

Summarized from public sources; check the original articles before acting on it.